Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia

This month's American Journal of Gastroenterology reports that Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.

News image

Fecal immunochemical testing (FIT) is increasingly used for colorectal cancer (CRC) screening.

Dr de Wijkerslooth and colleagues from Amsterdam, The Netherlands aimed to estimate its diagnostic accuracy in invitational population screening measured against colonoscopy.

Participants aged 50 to 75 years were asked in an invitational primary colonoscopy screening program to complete one sample FIT before colonoscopy.

The researchers estimated FIT sensitivity, specificity, and predictive values in detecting CRC and advanced neoplasia (carcinomas and advanced adenomas) for cutoff levels of 50 (FIT50), 75 (FIT75), and 100 (FIT100) ng hemoglobin (Hb)/ml, corresponding with, respectively, 10, 15 and 20 microgram Hb/g feces.

A total of 1,256 participants underwent a FIT and screening colonoscopy.

90% screening participants with CRC will be detected using one single FIT at low cutoff
American Journal of Gastroenterology

Advanced neoplasia was detected by colonoscopy in 9%, 0.6% of them had CRC.

At FIT50, 10% had a positive test result; 37% had advanced neoplasia and 6% had CRC.

A total of 74 of 1,135 FIT50 negatives had advanced neoplasia including 1 CRC.

FIT50 had a sensitivity of 38% for advanced neoplasia and 88% for CRC at a specificity of 93% and 91%, respectively.

the team found that the positive and negative predictive values for FIT50 were 6% and almost 100% for CRC, and 37% and 93% for advanced neoplasia.

The researchers found that sensitivity and specificity of FIT75 for advanced neoplasia were 33% and 96%.

At FIT100, 71 screenees had a positive test result.

The sensitivity and specificity of FIT100 were for advanced neoplasia 31% and 97%, and for CRC 75% and 95%.

The team noted that the area under curve for detecting advanced neoplasia was 0.70.

FIT had a similar sensitivity for proximal and distal advanced neoplasia at cutoffs of 50, 75 and 100 ng Hb/ml.

Dr de Wijkerslooth's team conclude, "90% screening participants with CRC and 40% with advanced neoplasia will be detected using one single FIT at low cutoff."

"Sensitivity in detecting proximal and distal advanced neoplasia is comparable."

Am J Gastroenterol 2012: 107: 1570-78
12 October 2012

Go to top of page Email this page Email this page to a colleague

 02 April 2015

Advanced search
 02 April 2015 
Physical activity and NAFLD
 02 April 2015 
Genetic risk for Crohn's disease
 02 April 2015 
EUS for detection of pancreatic neuroendocrine tumors
 01 April 2015 
Analysis of liver fibrosis
 01 April 2015 
Obeticholic acid in primary biliary cirrhosis
 01 April 2015 
Mortality rates for upper GI bleeds
 31 March 2015 
HCV-HIV co-infection combination therapy
 31 March 2015 
Placement of nasoenteral feeding tubes
 31 March 2015 
Hepatic fat and gallbladder polyps
 30 March 2015 
Minimally invasive approach in colorectal procedures
 30 March 2015 
Prevalence of IBD in USA residents of Indian ancestry
 30 March 2015 
Treatment of pediatric IBD
 27 March 2015 
Screening for fecal incontinence
 27 March 2015 
Deep remission in Crohn's disease
 27 March 2015 
Sexual functioning in IBD
 26 March 2015 
Survival of untreated hepatocellular carcinoma
 26 March 2015 
Antimicrobial therapy in cirrhosis with spontaneous bacterial peritonitis
 26 March 2015 
Metformin as a chemopreventive agent for Barrett's
 25 March 2015 
Genetics and Crohn's disease
 25 March 2015 
Mortality in Barrett’s–related T1 esophageal adenocarcinoma
 25 March 2015 
Cytomegalovirus and IBD
 24 March 2015 
Prevention of colorectal cancer after screening
 24 March 2015 
Functional GI disorders and body mass index
 24 March 2015 
Quality of life in children with fecal incontinence
 23 March 2015 
Fibrosis in NAFLD vs NASH
 23 March 2015 
The unmasking of Whipple's disease
 23 March 2015 
Predicting the quality of colon cancer care
 20 March 2015 
Interventions for eosinophilic esophagitis
 20 March 2015 
Screening for Barrett's esophagus
 20 March 2015 
Colorectal cancer risk and genetic variants
 19 March 2015 
Dedicated care for diverticular disease
 19 March 2015 
Hypnotherapy for IBS
 19 March 2015 
Poor mental and physical health in HCV
 18 March 2015 
Practice guidelines for colorectal polyps
 18 March 2015 
Out-of-hours endoscopy for upper GI bleeding
 18 March 2015 
H. pylori eradication and lipids
 17 March 2015 
H. pylori test-and-treat program and gastric cancer
 17 March 2015 
Adalimumab in Crohn’s disease
 17 March 2015 

Low-dose PPIs and GI bleeding in patients receiving aspirin

 16 March 2015 
Microscopic colitis
 16 March 2015 
Cholestasis of pregnancy with HCV
 16 March 2015 
Hybrid therapy for H. pylori
 13 March 2015 

Racial disparities in gluten-sensitive problems

 13 March 2015 
Medicare patients and payments to gastroenterologists
 13 March 2015 
Appendectomy in ulcerative colitis
 12 March 2015 
Predicting IBD in IBS patients
 12 March 2015 
Patient knowledge of IBS
 12 March 2015 
Nonceliac gluten sensitivity
 11 March 2015 

Prediction of malignant bile duct obstruction

 11 March 2015 
NAFLD–related hepatocellular carcinoma
 11 March 2015 
Assessment of eosinophilic esophagitis
 10 March 2015 
Risk for gastroesophageal reflux symptoms
 10 March 2015 
Poor disease course in pediatric ulcerative colitis
 10 March 2015 
Outcomes in Crohn's therapy
 09 March 2015 
Fibre usage in ulcerative colitis in remission
 09 March 2015 
Risk of C. difficile upon hospital admission
 09 March 2015 
Gastric Cancer detection during GI endosocopy
 06 March 2015 
Steroid therapy for eosinophilic esophagitis
 06 March 2015 
Second anti-TNF in IBD
 06 March 2015 
Efficacy of Hep E vaccine

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us